IBDEI0BN ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5269,1,4,0)
 ;;=4^R34.
 ;;^UTILITY(U,$J,358.3,5269,2)
 ;;=^5019333
 ;;^UTILITY(U,$J,358.3,5270,0)
 ;;=K76.7^^27^343^9
 ;;^UTILITY(U,$J,358.3,5270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5270,1,3,0)
 ;;=3^Hepatorenal Syndrome
 ;;^UTILITY(U,$J,358.3,5270,1,4,0)
 ;;=4^K76.7
 ;;^UTILITY(U,$J,358.3,5270,2)
 ;;=^56497
 ;;^UTILITY(U,$J,358.3,5271,0)
 ;;=N00.0^^27^344^8
 ;;^UTILITY(U,$J,358.3,5271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5271,1,3,0)
 ;;=3^Acute nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,5271,1,4,0)
 ;;=4^N00.0
 ;;^UTILITY(U,$J,358.3,5271,2)
 ;;=^5015491
 ;;^UTILITY(U,$J,358.3,5272,0)
 ;;=N00.1^^27^344^7
 ;;^UTILITY(U,$J,358.3,5272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5272,1,3,0)
 ;;=3^Acute nephritic syndrome w/ focal and segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,5272,1,4,0)
 ;;=4^N00.1
 ;;^UTILITY(U,$J,358.3,5272,2)
 ;;=^5015492
 ;;^UTILITY(U,$J,358.3,5273,0)
 ;;=N00.2^^27^344^4
 ;;^UTILITY(U,$J,358.3,5273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5273,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,5273,1,4,0)
 ;;=4^N00.2
 ;;^UTILITY(U,$J,358.3,5273,2)
 ;;=^5015493
 ;;^UTILITY(U,$J,358.3,5274,0)
 ;;=N00.3^^27^344^5
 ;;^UTILITY(U,$J,358.3,5274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5274,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5274,1,4,0)
 ;;=4^N00.3
 ;;^UTILITY(U,$J,358.3,5274,2)
 ;;=^5015494
 ;;^UTILITY(U,$J,358.3,5275,0)
 ;;=N00.4^^27^344^3
 ;;^UTILITY(U,$J,358.3,5275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5275,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5275,1,4,0)
 ;;=4^N00.4
 ;;^UTILITY(U,$J,358.3,5275,2)
 ;;=^5015495
 ;;^UTILITY(U,$J,358.3,5276,0)
 ;;=N00.5^^27^344^6
 ;;^UTILITY(U,$J,358.3,5276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5276,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,5276,1,4,0)
 ;;=4^N00.5
 ;;^UTILITY(U,$J,358.3,5276,2)
 ;;=^5015496
 ;;^UTILITY(U,$J,358.3,5277,0)
 ;;=N00.6^^27^344^1
 ;;^UTILITY(U,$J,358.3,5277,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5277,1,3,0)
 ;;=3^Acute nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,5277,1,4,0)
 ;;=4^N00.6
 ;;^UTILITY(U,$J,358.3,5277,2)
 ;;=^5015497
 ;;^UTILITY(U,$J,358.3,5278,0)
 ;;=N00.7^^27^344^2
 ;;^UTILITY(U,$J,358.3,5278,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5278,1,3,0)
 ;;=3^Acute nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,5278,1,4,0)
 ;;=4^N00.7
 ;;^UTILITY(U,$J,358.3,5278,2)
 ;;=^5015498
 ;;^UTILITY(U,$J,358.3,5279,0)
 ;;=N00.8^^27^344^9
 ;;^UTILITY(U,$J,358.3,5279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5279,1,3,0)
 ;;=3^Acute nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,5279,1,4,0)
 ;;=4^N00.8
 ;;^UTILITY(U,$J,358.3,5279,2)
 ;;=^5015499
 ;;^UTILITY(U,$J,358.3,5280,0)
 ;;=N00.9^^27^344^10
 ;;^UTILITY(U,$J,358.3,5280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5280,1,3,0)
 ;;=3^Acute nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,5280,1,4,0)
 ;;=4^N00.9
 ;;^UTILITY(U,$J,358.3,5280,2)
 ;;=^5015500
 ;;^UTILITY(U,$J,358.3,5281,0)
 ;;=N01.0^^27^344^70
 ;;^UTILITY(U,$J,358.3,5281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5281,1,3,0)
 ;;=3^Rapidly progr neph synd w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,5281,1,4,0)
 ;;=4^N01.0
 ;;^UTILITY(U,$J,358.3,5281,2)
 ;;=^5015501
 ;;^UTILITY(U,$J,358.3,5282,0)
 ;;=N01.1^^27^344^69
